• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of a novel predictive markers for HCC development using exosomal miRNA information in patients with chronic hepatitis B virus infection

Research Project

Project/Area Number 18K15792
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionOsaka City University

Principal Investigator

Kozuka Ritsuzo  大阪市立大学, 大学院医学研究科, 病院講師 (10726657)

Project Period (FY) 2018-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
KeywordsB型肝炎 / 肝発癌 / エクソソーム / マイクロRNA
Outline of Final Research Achievements

We analyzed exosomal miRNA associated with progression of liver fibrosis in patients with chronic hepatitis B virus infection, and identified five miRNAs, i.e., miR-3648, miR-3665, miR-122-5p, miR-3960, and miR-4739. In addition, we analyzed miRNAs that correlate with development of hepatocellular carcinoma (HCC) in patients treated and untreated with nucleos(t)ide analogue (NA), and identified that predictive accuracy of HCC development is increased by using a combination of 22 miRNA expression patterns in patients untreated with NA. However, it was impossible to predict by using this combination in patients treated with NA. The miRNA expression pattern that predicts HCC development in patients with chronic hepatitis B virus infection differs between patients treated and untreated with NA, suggesting that NA treatment may change the mechanism of HCC development.

Academic Significance and Societal Importance of the Research Achievements

B型肝炎ウイルスを完全に排除する治療法はなく、多くのB型慢性肝疾患患者に核酸アナログ(NA)治療が行われ、肝発癌をいかに抑制するかが最大の治療目標となっている。一方、肝線維化進展や肝発癌を予測できるバイオマーカーの開発が望まれるが、血清エクソソーム中のmiRNAは安定性が高く、新たなバイオマーカーとして期待される。本研究では、肝線維化進展や肝発癌と相関する血清エクソソーム中のmiRNAを同定した。また、肝発癌予測に関するmiRNA発現パターンがNA治療の有無により異なり、肝発癌メカニズムがNAで変化することが示され、NAによる肝発癌抑制の機序を明らかにしたことは学術的に意義が高いと考えられる。

Report

(5 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (3 results)

All 2022 2021 2020

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (2 results)

  • [Journal Article] Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.2022

    • Author(s)
      Ritsuzo Kozuka, Masaru Enomoto, Minh Phuong Dong, Hoang Hai, Le Thi Thanh Thuy, Naoshi Odagiri, Kanako Yoshida, Kohei Kotani, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Akihiro Tamori, Norifumi Kawada
    • Journal Title

      Scientific reports

      Volume: 12 Issue: 1 Pages: 105-105

    • DOI

      10.1038/s41598-021-03706-w

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] 可溶性免疫チェックポイント分子から見た核酸アナログによるHBV制御後の肝発癌危険因子の検討2021

    • Author(s)
      小塚立蔵
    • Organizer
      第57回日本肝臓学会総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 核酸アナログによるHBV制御後のHLA-SNPを用いた肝癌サーベイランスについて2020

    • Author(s)
      小塚立蔵
    • Organizer
      第56回日本肝癌研究会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi